
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
NewAmsterdam Pharma Company N.V. Warrant (NAMSW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NAMSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -27.34% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 |
52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2314.47% |
Management Effectiveness
Return on Assets (TTM) -18.15% | Return on Equity (TTM) -31.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 54899238 |
Shares Outstanding - | Shares Floating 54899238 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Warrant
Company Overview
History and Background
NewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on the research and development of therapies for metabolic diseases, particularly those affecting lipid metabolism. It went public through a reverse merger with Frazier Lifesciences Acquisition Corporation in 2022. The warrant represents the right to purchase shares of the combined company.
Core Business Areas
- Lipid Metabolism Therapies: Develops and commercializes therapies targeting lipid metabolism, focusing on cardiovascular disease.
Leadership and Structure
The leadership team comprises experienced pharmaceutical executives. The company has a typical organizational structure for a publicly traded biopharmaceutical firm, including research, development, and commercialization departments.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is their lead investigational product. It is a CETP inhibitor in Phase 3 clinical trials for lowering LDL cholesterol and reducing cardiovascular risk. Competitors include existing statins (e.g., Lipitor, Crestor) and other emerging lipid-lowering therapies like PCSK9 inhibitors (e.g., Repatha, Praluent). Market share is prospective, dependent on successful clinical trials and regulatory approval. No current revenue.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially the segment focused on cardiovascular diseases and lipid metabolism disorders, is a large and competitive market. Driven by aging populations and increasing prevalence of related conditions.
Positioning
NewAmsterdam Pharma aims to address unmet needs in lipid management, particularly for patients who do not achieve sufficient LDL-C lowering with existing therapies. Their success depends heavily on the clinical and commercial performance of Obicetrapib.
Total Addressable Market (TAM)
The global lipid-lowering drug market is estimated to be worth hundreds of billions of dollars. NewAmsterdam Pharma's positioning within this TAM is dependent on clinical trial outcomes and regulatory approval of Obicetrapib. If successful, they could capture a significant portion of the market currently addressed by statins and PCSK9 inhibitors.
Upturn SWOT Analysis
Strengths
- Promising lead compound (Obicetrapib)
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Single product focus (Obicetrapib)
- Reliance on clinical trial success
- Potential for regulatory hurdles
- No current product revenue
Opportunities
- Potential for partnership or acquisition
- Expansion into new indications
- Positive clinical trial results
- Favorable regulatory environment
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Adverse regulatory decisions
- Patent challenges
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- NVO
Competitive Landscape
NewAmsterdam Pharma faces significant competition from large, established pharmaceutical companies with extensive resources and existing products for lipid management. Their competitive advantage relies on demonstrating superior efficacy and safety of Obicetrapib.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is non-existent as a clinical stage company without revenue.
Future Projections: Future growth is entirely dependent on the successful development and commercialization of Obicetrapib. Analyst estimates vary widely based on clinical trial assumptions.
Recent Initiatives: Focus on advancing Obicetrapib through Phase 3 clinical trials and preparing for potential regulatory submissions.
Summary
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company with a high-risk, high-reward profile. Its success hinges on the outcome of Obicetrapib's clinical trials and subsequent regulatory approval. The company faces strong competition and financial risks but also has the potential for significant growth if Obicetrapib proves to be a successful therapy. Investors should closely monitor clinical trial results and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Data is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | |
Full time employees 77 |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.